deltatrials
Completed PHASE2 INTERVENTIONAL 8-arm NCT03903822

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWICE DAILY FOR 6 WEEKS IN PARTICIPANTS WITH MILD OR MODERATE ATOPIC DERMATITIS

Sponsor: Pfizer

Updated 21 times since 2019 Last updated: Mar 3, 2021 Started: May 13, 2019 Primary completion: May 7, 2020 Completion: May 7, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Atopic Dermatitis and is currently completed. Pfizer leads this study, which shows 21 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jul 2024 · 39 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Apr 2021 [monthly]

    Completed PHASE2

Show 16 earlier versions
  1. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jul 2020 — Aug 2020 [monthly]

    Completed PHASE2

    Status: RecruitingCompleted

  3. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  4. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  5. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  6. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  8. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  9. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  10. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  11. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  12. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  13. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  14. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  15. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  16. May 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .